Current and anticipated future use of MRD in hematological and solid tumors

Abstract

The minimal residual disease (MRD) testing landscape is rapidly evolving and increasingly playing an important role in both clinical routing practice and in clinical trials settings. Where MRD testing has predominantly been applied in hematological tumors it is also progressively finding use in solid tumors.

This report leverages Diaceutics unique and proprietary range of US testing data combined with primary market research (PMR) from both hematologists and oncologists alongside insights from Diaceutics team of precision medicine experts and global lab team to create a unique understanding of the highly topical subject and is unlike any other report currently available on the market.

It delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. It provides insights into key questions around the current and future use of MRD in both hematological and solid tumor indications and provides an understanding of key factors affecting MRD strategies in drug development and commercialization.